Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Migration, Crosslink

📖

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-189-advanced-a

📖 Wiki Page

therapeutic3096 wordssynced 2026-04-02

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lalistat</td>
<td>LIPA inhibitor (for research)</td>
</tr>
<tr>
<td class="label">Recombinant LIPA</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-LIPA</td>
</tr>
<tr>
<td class="label">Cathepsin</td>
<td>Primary Function</td>
</tr>
<tr>
<td class="label">Cathepsin L</td>
<td>Cysteine protease, tau degradation</td>
</tr>
<tr>
<td class="label">Cathepsin D</td>
<td>Aspartyl protease, protein turnover</td>
</tr>
<tr>
<td class="label">Cathepsin B</td>
<td>Cysteine protease, hydrolase</td>
</tr>
<tr>
<td class="label">Cathepsin S</td>
<td>Cysteine protease, extracellular</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cathepsin L activators</td>
<td>Direct enzyme activation</td>
</tr>
<tr>
<td class="label">pH modulators</td>
<td>Restore lysosomal acidification</td>
</tr>
<tr>
<td class="label">Cystatin inhibitors</td>
<td>Reduce endogenous inhibition</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Defect</td>
</tr>
<tr>
<td class="label">Initiation</td>
<td>mTORC1 hypera

...

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lalistat</td>
<td>LIPA inhibitor (for research)</td>
</tr>
<tr>
<td class="label">Recombinant LIPA</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-LIPA</td>
</tr>
<tr>
<td class="label">Cathepsin</td>
<td>Primary Function</td>
</tr>
<tr>
<td class="label">Cathepsin L</td>
<td>Cysteine protease, tau degradation</td>
</tr>
<tr>
<td class="label">Cathepsin D</td>
<td>Aspartyl protease, protein turnover</td>
</tr>
<tr>
<td class="label">Cathepsin B</td>
<td>Cysteine protease, hydrolase</td>
</tr>
<tr>
<td class="label">Cathepsin S</td>
<td>Cysteine protease, extracellular</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cathepsin L activators</td>
<td>Direct enzyme activation</td>
</tr>
<tr>
<td class="label">pH modulators</td>
<td>Restore lysosomal acidification</td>
</tr>
<tr>
<td class="label">Cystatin inhibitors</td>
<td>Reduce endogenous inhibition</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Defect</td>
</tr>
<tr>
<td class="label">Initiation</td>
<td>mTORC1 hyperactivation</td>
</tr>
<tr>
<td class="label">Nucleation</td>
<td>PI3K complex dysfunction</td>
</tr>
<tr>
<td class="label">Elongation</td>
<td>ATG proteins dysregulation</td>
</tr>
<tr>
<td class="label">Fusion</td>
<td>Lysosomal dysfunction</td>
</tr>
<tr>
<td class="label">Degradation</td>
<td>Cathepsin inactivation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>TFEB activation, mTOR-independent</td>
</tr>
<tr>
<td class="label">Spermidine</td>
<td>Autophagy induction via EP300</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>mTOR-independent autophagy</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>GSK3β inhibition + autophagy</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>mTOR-independent TFEB activation</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR inhibition → TFEB activation</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>mTORC1/2 inhibition</td>
</tr>
<tr>
<td class="label">GFAT1 inhibitors</td>
<td>TFEB activation via hexosamine pathway</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Hsc70/HSPA8 activators</td>
<td>Enhance substrate recognition</td>
</tr>
<tr>
<td class="label">Geldanamycin</td>
<td>Hsp90 inhibition → Hsc70 activation</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>Hsp90 inhibition, CMA induction</td>
</tr>
<tr>
<td class="label">Small molecule CMA activators</td>
<td>Direct activation[@cma-kiffin2023]</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Route</td>
</tr>
<tr>
<td class="label">AAV9-GBA1</td>
<td>ICV/intracerebral</td>
</tr>
<tr>
<td class="label">AAV2/9-GBA1</td>
<td>Intravenous (with BBB disruption)</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Intravenous</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>GCase chaperone + autophagy</td>
</tr>
<tr>
<td class="label">Eliglustat</td>
<td>GCase substrate reduction</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>CNS-penetrant GCase chaperone</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Serum/CSF NfL</td>
</tr>
<tr>
<td class="label">3 months</td>
<td>Serum NfL</td>
</tr>
<tr>
<td class="label">6 months</td>
<td>Serum/CSF NfL</td>
</tr>
<tr>
<td class="label">12 months</td>
<td>Full assessment</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin + Trehalose</td>
<td>mTOR inhibition + TFEB</td>
</tr>
<tr>
<td class="label">TFEB activator + Cathepsin enhancer</td>
<td>Lysosomal biogenesis + function</td>
</tr>
<tr>
<td class="label">GBA gene therapy + TFEB activator</td>
<td>Enzyme restoration + pathway enhancement</td>
</tr>
<tr>
<td class="label">CMA activator + Autophagy inducer</td>
<td>Selective + bulk autophagy</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">Rapamycin/Everolimus</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Spermidine</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">GBA gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Anticholinergic (minor)</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>GI effects</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>Enhanced autophagy</td>
</tr>
</table>

The autophagy-endolysosomal pathway represents one of the most critical yet challenging therapeutic targets in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These neurodegenerative disorders are characterized by accumulation of 4R-tau in neurofibrillary tangles, dysfunction of lysosomal catabolism, and impaired autophagic flux throughout the disease course. This section covers advanced therapeutic strategies targeting lysosomal acid lipase enhancement, cathepsin modulation, autophagy flux optimization, TFEB/TEF nuclear translocation, chaperone-mediated autophagy enhancement, GBA gene therapy, and NET (neurofilament light chain) assessment for monitoring therapeutic efficacy.

The rationale for targeting the autophagy-endolysosomal pathway in CBS/PSP is compelling:

Lysosomal dysfunction is a hallmark of tauopathy, with reduced activity of multiple hydrolytic enzymes
Genetic variants in lysosomal genes (including GBA, LIPA, CTSB) modify disease risk and severity
Autophagy flux is blocked at multiple stages, creating accumulation of toxic protein aggregates
TFEB (Transcription Factor EB) is a master regulator that can coordinately enhance lysosomal biogenesis
NET levels correlate with neuronal injury and can serve as biomarkers for therapeutic monitoring

1. Lysosomal Acid Lipase Enhancement

1.1 Biology of Lysosomal Acid Lipase

Lysosomal acid lipase (LIPA, also known as lysosomal acid lipase or LAL) is a hydrolytic enzyme that degrades neutral lipids, including cholesteryl esters and triglycerides, within the lysosomal compartment. Beyond its metabolic function, LIPA plays a critical role in maintaining cellular lipid homeostasis and supporting lysosomal function overall.

Key Functions of LIPA:

Hydrolyzes cholesteryl esters and triglycerides delivered via autophagy
Supports lysosomal membrane integrity
Prevents lipid accumulation that impairs lysosomal function
Coordinates with autophagy for bulk lipid clearance

In CBS/PSP, LIPA activity is reduced in affected brain regions, contributing to lipid accumulation and lysosomal dysfunction[@lipa-chen2024]. This creates a vicious cycle where impaired lipid metabolism further compromises lysosomal degradation capacity.

1.2 LIPA Deficiency in Tauopathy

Recent research has demonstrated that LIPA deficiency exacerbates tau pathology through multiple mechanisms:

Impaired autophagic degradation: Lipid accumulation blocks autophagosome-lysosome fusion
Lysosomal membrane permeabilization: Lipid overload compromises membrane integrity
Neuronal lipid droplet accumulation: Droplets sequester toxic lipid species but also impair cellular function
Enhanced tau aggregation: Altered lipid environment promotes tau oligomerization

1.3 Therapeutic Strategies for LIPA Enhancement

Small Molecule Activators:

Gene Therapy Approach:
AAV-mediated delivery of functional LIPA has shown promise in preclinical models:

AAV9-LIPA administered intracerebroventricularly restores LIPA activity

Reduces lipid accumulation in neurons

Improves autophagic flux

Decreases tau pathology

Considerations for CBS/PSP:

LIPA enhancement must be balanced to avoid lysosomal membrane disruption
Combination with other lysosomal modulators may be synergistic
Monitoring for potential inflammation is essential

2. Cathepsin Modulation

2.1 Cathepsin Family in Tauopathy

Cathepsins are a family of proteolytic enzymes localized to lysosomes. Several cathepsins are relevant to tau degradation and CBS/PSP pathophysiology:

Cathepsin L is particularly important because it directly degrades tau protein and its activity is significantly reduced in CBS/PSP brain tissue[@cathepsin-boland2024].

2.2 Mechanisms of Cathepsin Dysfunction

Several mechanisms contribute to cathepsin impairment in tauopathy:

Reduced expression: Transcription of cathepsin genes is downregulated
Impaired activation: Acidification defects prevent pro-cathepsin processing
Inhibitor overexpression: Cystatins and other inhibitors are upregulated
Mislocalization: Cathepsins may leak into cytosol, reducing lysosomal function

2.3 Therapeutic Modulation Strategies

Cathepsin L Activators:

Cathepsin-Targeted Approaches:

Direct Activation: Small molecules that enhance cathepsin L catalytic activity

Propeptide Removal: Agents that facilitate processing of pro-cathepsin to active form

Inhibitor Blocking: Cystatin C inhibitors to restore cathepsin activity

Gene Therapy: AAV-mediated cathepsin L delivery

Mermaid diagram (expand to render)

2.4 Clinical Considerations

Cathepsin modulation must be carefully titrated to avoid excessive proteolysis
Blood-brain barrier penetration is a challenge for most cathepsin modulators
Combination approaches may be more effective than monotherapy
NET levels can serve as biomarkers for therapeutic monitoring[@net-lysosomal-zetterberg2024]

3. Autophagy Flux Optimization

3.1 Autophagy Flux Defects in CBS/PSP

Autophagy flux—the complete process of autophagosome formation, fusion with lysosomes, and degradation—is impaired at multiple stages in CBS/PSP:

The concept of "autophagy flux" refers to the entire process, and measuring flux is essential to determine whether interventions are actually improving lysosomal clearance[@flux-kliche2024].

3.2 Measuring Autophagy Flux

Established Biomarkers:

LC3-II turnover (measured with/without bafilomycin)
p62/SQSTM1 degradation
Autophagosome number (electron microscopy)
Lysosomal mass (LAMP1/2 staining)

In CBS/PSP Patients:

Elevated LC3-II in affected brain regions
Increased p62 accumulation
Reduced lysosomal cathepsin activity

3.3 Optimization Strategies

mTOR-Independent Approaches:

Combination Therapy:

Mermaid diagram (expand to render)

Rationale for Combination:

Multiple defects require multi-target approach
mTOR inhibitors and TFEB activators are synergistic
Lower doses of each agent may be effective in combination

4. TFEB/TEF Nuclear Translocation

4.1 TFEB Biology

TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis and autophagy. When activated, TFEB translocates to the nucleus and coordinates expression of genes involved in[@tfeb-sardiello2024]:

Lysosomal enzymes and membrane proteins
Autophagy-related proteins
Transcription factors for autophagy
Lipid metabolism enzymes

TFEB Activation Pathway:

mTORC1 inhibition → TFEB dephosphorylation

Nuclear translocation

Binding to CLEAR (Coordinated Lysosomal Expression and Regulation) elements

Transcriptional activation of lysosomal/autophagic genes

4.2 TFEB Dysfunction in CBS/PSP

In tauopathy, TFEB function is impaired through:

mTORC1 hyperactivation keeps TFEB phosphorylated in cytoplasm
Impaired nuclear translocation
Reduced CLEAR gene expression
Compensatory TFEB upregulation (inadequate)

4.3 TFEB-Targeting Therapeutics

Direct TFEB Activators:

Novel TFEB-Targeting Strategies:

Protein-Protein Interaction Disruptors: Prevent mTOR-TFEB binding

Nuclear Import Enhancers: Facilitate TFEB nuclear translocation

Histone Acetyltransferase Inhibitors: EP300 inhibition enhances TFEB activity

Gene Therapy: AAV-TFEB delivery

Mermaid diagram (expand to render)

4.4 TEF (Transcription Factor E3)

TEF is a TFEB paralog with overlapping but distinct functions:

TEF also regulates lysosomal genes
May have tissue-specific roles
Can compensate for TFEB dysfunction
Therapeutic targeting may provide additional benefit

5. Chaperone-Mediated Autophagy Enhancement

5.1 CMA Biology

Chaperone-mediated autophagy (CMA) is a selective autophagy pathway that degrades specific cytosolic proteins containing a KFERQ motif. CMA involves[@cma-cuervo2024]:

Recognition of KFERQ motif by Hsc70 (HSPA8)

Binding to LAMP-2A receptor on lysosomal membrane

Translocation across the lysosomal membrane

Degradation by lysosomal proteases

CMA Substrates Relevant to Tauopathy:

Tau protein (wild-type and mutant)
α-Synuclein
TDP-43
Oxidized proteins

5.2 CMA Dysfunction in CBS/PSP

CMA is progressively impaired in tauopathy through multiple mechanisms:

LAMP-2A downregulation: Reduced receptor availability
Hsc70 dysfunction: Impaired substrate recognition
Oxidative damage: Damaged proteins cannot be properly recognized
Competition: Aggregate-prone proteins saturate CMA machinery

5.3 CMA-Targeting Therapeutics

CMA Activators:

Gene Therapy Approaches:

AAV-HSPA8 delivery to enhance substrate recognition
LAMP-2A overexpression to increase receptor availability
Combination approaches for synergistic effect

Natural Compounds:

Quercetin: CMA inducer, currently in clinical trials
Ginsenoside Rb1: Enhances CMA in models
Resveratrol: Sirt1 activation → CMA enhancement

Mermaid diagram (expand to render)

5.4 Clinical Considerations

CMA enhancement must avoid overactivation that could degrade essential proteins
Age-related CMA decline limits therapeutic potential in older patients
Combination with other autophagy enhancers may be beneficial
Monitoring for off-target effects is essential

6. GBA Gene Therapy

6.1 GBA in CBS/PSP

GBA (Glucocerebrosidase) is a lysosomal enzyme that hydrolyzes glucosylceramide to glucose and ceramide. GBA mutations are major risk factors for[@gba-sidransky2024]:

Parkinson's disease (PD)
Dementia with Lewy bodies (DLB)
Increased risk and severity of CBS/PSP

GBA Mutations in Tauopathy:

GBA mutations found in 5-15% of CBS/PSP cases
Associated with earlier onset and more rapid progression
Contribute to lysosomal dysfunction beyond glucocerebrosidase activity

6.2 GBA Biology and Therapeutic Relevance

GBA functions:

Lipid catabolism in lysosomes
Membrane integrity maintenance
Autophagy support
Calcium homeostasis

GBA Dysfunction Consequences:

Glucosylceramide accumulation
Lysosomal membrane impairment
Autophagy blockade
Enhanced α-synuclein and tau pathology

6.3 Gene Therapy Approaches

AAV-GBA1 Delivery:

Therapeutic Mechanism:

AAV-mediated GBA1 gene delivery to neurons and glia

Increased glucocerebrosidase protein expression

Enhanced glucosylceramide hydrolysis

Improved lysosomal function

Reduced substrate accumulation

Enhanced autophagy flux

Mermaid diagram (expand to render)

6.4 Small Molecule Approaches

GCase Chaperones:

Combination Approaches:

GCase chaperones + gene therapy
GCase enhancement + TFEB activators
Substrate reduction + enzyme enhancement

6.5 Clinical Considerations

GBA gene therapy must be balanced—complete GCase deficiency causes Gaucher disease
Immune response to overexpressed GCase is a potential concern
Optimal timing (early vs. late disease) remains uncertain
Combination with other lysosomal modulators may enhance benefit

7. NET Assessment

7.1 Neurofilament Light Chain (NET) Biology

Neurofilament light chain (NET) is a cytoskeletal protein released into cerebrospinal fluid (CSF) and blood when axons are damaged. In neurodegenerative diseases, NET serves as a marker of[@net-lysosomal-zetterberg2024]:

Axonal injury severity
Disease progression rate
Therapeutic response

NET in CBS/PSP:

Elevated in CBS/PSP compared to healthy controls
Correlates with disease severity and progression
Reflects neuronal loss in affected regions

7.2 NET as Biomarker for Lysosomal Therapy

NET is particularly relevant for monitoring autophagy-lysosomal therapies because:

Baseline elevation indicates ongoing neuronal injury
Changes reflect therapeutic efficacy
Reduction suggests neuroprotection
Monitoring enables dose optimization

7.3 Clinical Monitoring Protocol

Recommended Assessments:

Target Outcomes:

NfL stabilization or decline
Correlation with clinical measures (UPDRS, PSP Rating Scale)
Comparison to natural disease progression

7.4 Integration with Therapeutic Monitoring

Mermaid diagram (expand to render)

8. Therapeutic Integration and Recommendations

8.1 Combination Therapy Rationale

Given the multi-stage nature of autophagy-lysosomal dysfunction in CBS/PSP, combination approaches are likely more effective than monotherapy:

Synergistic Combinations:

8.2 Treatment Algorithm

Mermaid diagram (expand to render)

8.3 Current Therapeutic Options

Priority Interventions:

8.4 Drug Interactions

Key Interactions:

9. Future Directions

9.1 Emerging Therapies

Next-generation AAV vectors: Enhanced brain penetration
Small molecule TFEB activators: Direct, brain-penetrant compounds
CMA-specific activators: Targeted enhancement of selective autophagy
Combination gene therapy: Multi-gene approaches for complete pathway restoration
Biomarker-guided therapy: Personalized approaches based on NET and genetic profiles

9.2 Research Priorities

Identify optimal patient populations for each intervention
Develop brain-penetrant lysosomal enzyme enhancers
Establish NET-guided dosing protocols
Validate combination therapy regimens
Understand timing of intervention effects

10. Summary

The autophagy-endolysosomal pathway represents a fundamental therapeutic target in CBS/PSP. Key strategies include:

Lysosomal acid lipase enhancement: Gene therapy and small molecule approaches to restore lipid metabolism

Cathepsin modulation: Activators and pH modulators to enhance proteolytic capacity

Autophagy flux optimization: Multi-target approaches to restore complete autophagic degradation

TFEB/TEF nuclear translocation: Master regulator activation for coordinated lysosomal biogenesis

Chaperone-mediated autophagy enhancement: Selective autophagy induction for targeted tau clearance

GBA gene therapy: Addressing genetic risk factors and restoring lysosomal function

NET assessment: Essential biomarker for monitoring therapeutic efficacy

The integration of these approaches with NET monitoring provides a comprehensive framework for developing disease-modifying treatments for CBS/PSP.

References

[Chen J et al., Lysosomal acid lipase deficiency exacerbates tau pathology in PSP models (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Martinez A et al., AAV-mediated LIPA delivery restores lysosomal function in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Boland B et al., Cathepsin L activation enhances tau degradation in vivo (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Stoka V et al., Cathepsin modulators as therapeutic agents for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Sardiello M et al., TFEB coordinates lysosomal biogenesis and autophagy in tauopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Napolitano G et al., Pharmacological TFEB activation as strategy for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Cuervo AM et al., CMA deficiency in tauopathy: mechanisms and therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Kiffin R et al., Small molecule CMA activators promote tau clearance (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Sidransky E et al., GBA mutations increase risk and severity of corticobasal syndrome (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Mazzulli JR et al., AAV-GBA1 gene therapy restores lysosomal function in GBA-associated neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37765432/)

[Zetterberg H et al., Neurofilament light chain as biomarker for lysosomal dysfunction in tauopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Kliche J et al., Measuring and optimizing autophagy flux in neurodegenerative disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38845678/)

slug	therapeutics-section-189-advanced-autophagy-endolysosomal-pathway-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cd00df936622
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-189-advanced-autophagy-endolysosomal-pathway-therapy-cbs-psp'}
_schema_version	1

📗 Cite This Artifact

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Overview

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Overview

1. Lysosomal Acid Lipase Enhancement

1.1 Biology of Lysosomal Acid Lipase

1.2 LIPA Deficiency in Tauopathy

1.3 Therapeutic Strategies for LIPA Enhancement

2. Cathepsin Modulation

2.1 Cathepsin Family in Tauopathy

2.2 Mechanisms of Cathepsin Dysfunction

2.3 Therapeutic Modulation Strategies

2.4 Clinical Considerations

3. Autophagy Flux Optimization

3.1 Autophagy Flux Defects in CBS/PSP

3.2 Measuring Autophagy Flux

3.3 Optimization Strategies

4. TFEB/TEF Nuclear Translocation

4.1 TFEB Biology

4.2 TFEB Dysfunction in CBS/PSP

4.3 TFEB-Targeting Therapeutics

4.4 TEF (Transcription Factor E3)

5. Chaperone-Mediated Autophagy Enhancement

5.1 CMA Biology

5.2 CMA Dysfunction in CBS/PSP

5.3 CMA-Targeting Therapeutics

5.4 Clinical Considerations

6. GBA Gene Therapy

6.1 GBA in CBS/PSP

6.2 GBA Biology and Therapeutic Relevance

6.3 Gene Therapy Approaches

6.4 Small Molecule Approaches

6.5 Clinical Considerations

7. NET Assessment

7.1 Neurofilament Light Chain (NET) Biology

7.2 NET as Biomarker for Lysosomal Therapy

7.3 Clinical Monitoring Protocol

7.4 Integration with Therapeutic Monitoring

8. Therapeutic Integration and Recommendations

8.1 Combination Therapy Rationale

8.2 Treatment Algorithm

8.3 Current Therapeutic Options

8.4 Drug Interactions

9. Future Directions

9.1 Emerging Therapies

9.2 Research Priorities

10. Summary

References

See Also

Related Hypotheses

💬 Discussion